Clinical Trial Update: Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)

View source ↗

Summary

Pfizer-sponsored clinical trial update on a 100 mg infliximab biosimilar for rheumatoid arthritis. The study status is completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Infliximab biosimilar

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Status: COMPLETED | Results posted: 2026-01-06